Immune Engineering SIG

Timeslot: Wednesday, April 21, 2021 - 3:15pm to 4:45pm
Track: Immunomodulatory Biomaterials
Room: Virtual


Over the past decade the focus of many bioengineers and clinicians has been shifting towards "immune engineering" approaches that include but are not limited to engineered biomaterials for vaccines, immunotherapy (immune-modulation), cell and gene therapy, immune microenvironment engineering, and systems immunology. These research areas embrace a comprehensive list of translational immunology-associated problems including chronic infections, autoimmune diseases, aggressive cancers, allergies, etc. The purpose of the Immune Engineering SIG is to bring together emerging ideas and provide a venue for professional interaction to a large number of academic and industrial research groups and scientists working in these areas.

Kara Spiller, PhD,
Lance Kam, PhD,
Rebecca Pompano, PhD


Abstracts will be available for download on April 20, 2021.

  • 95. An Antigen-Specific Microparticle System Shows Efficacy in a Mouse Model of Multiple Sclerosis, Alexander Kwiatkowski1, Joshua Stewart, PhD1, Eric Helm2, Theodore Drashansky, PhD2, Dorina Avram, PhD2,3, Benjamin Keselowsky, PhD11University of Florida, Gainesville, FL, USA, 2University of Florida, Gainesville, FL, USA, 3H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

  • 96. Lipid Nanoparticle-Mediated mRNA Delivery for CAR T Cell Engineering, Margaret Billingsley, Michael Mitchell, PhDUniversity of Pennsylvania, Philadelphia, PA, USA

  • 99. Exogenous Delivery of Indoleamine 2,3-Dioxygenase Reverses Disease Severity in Psoriasis, Sabrina Macias, Marija Zovko, Isha Verma, Arun Wanchoo, PhD, Gregory Hudalla, PhD, Benjamin Keselowsky, PhDUniversity of Florida, Gainesville, FL, USA

  • 100. Quality of CD8+ T cell Immunity Evoked in Lymph Nodes is Compartmentalized by Route of Antigen Transport and Functional in Tumor Context, Meghan O'Melia1,2, Nathan Rohner1, Margaret Manspeaker1, David Francis1, Haydn Kissick2, Susan Thomas1,21Georgia Institute of Technology, Atlanta, GA, USA, 2Emory University, Atlanta, GA, USA

  • 101. PEGylation of Indoleamine 2,3-Dioxygenase for Addressing Systemic Immune Regulation, Jennifer Simonovich1, Arun Wanchoo1, Alexander Kwiatkowski1, Dorina Avram2, Gregory Hudalla1, Benjamin Keselowsky11University of Florida, Gainesville, FL, USA, 2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

  • 102. Liver targeting synthetic glycosylations: Engineering humoral tolerance to protein therapeutics, Scott Wilson, PhD1, Kym Brunggell, PhD2, Michal Raczy2, Rachel Wallace2, Andrew Tremain2, Jeffrey Hubbell, PhD21Johns Hopkins University, Baltimore, MD, USA, 2University of Chicago, Chicago, IL, USA